Dyne Therapeutics Inc(DYN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:31 PM ET (Korea 10/28 05:31)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.33 | Insider Own | 17.89% | Shs Outstand | 165.7M | Perf Week | 4.12% |
| Market Cap | 3.16B | Forward P/E | - | EPS next Y | 7.56% | Insider Trans | -14.11% | Shs Float | 153.3M | Perf Month | 3.67% |
| Enterprise Value | 2.50B | PEG | - | EPS next Q | -0.91 | Inst Own | 84.98% | Short Float | 16.61% | Perf Quarter | -32.51% |
| Income | -0.52B | P/S | - | EPS this Y | -4.49% | Inst Trans | 1.15% | Short Ratio | 9.16 | Perf Half Y | -6.72% |
| Sales | 0.00B | P/B | 4 | EPS next 5Y | 9.75% | ROA | -60.29% | Short Interest | 25.47M | Perf YTD | -13.39% |
| Book/sh | 4.24 | P/C | 3.52 | EPS past 3/5Y | -2.41% 3.39% | ROE | -81.57% | 52W High | -37.96% ($27.31) | Perf Year | -29.91% |
| Cash/sh | 4.81 | P/FCF | - | Sales past 3/5Y | - | ROIC | -56.7% | 52W Low | 21% ($14.00) | Perf 3Y | 155.89% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.71% | Gross Margin | - | Volatility(W/M) | 5.17% 5.35% | Perf 5Y | 18.63% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.91 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.02 | EPS Q/Q | -10.86% | Profit Margin | - | RSI (14) | 52.21 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.02 | Sales Q/Q | - | SMA20 | 7.76% ($15.72) | Beta | 1.23 | Target Price | $36 |
| Payout | - | Debt/Eq | 0.33 | Earnings | 2026/7/29 | SMA50 | -11.27% ($19.09) | Rel Volume | 1.08 | Prev Close | $15.72 |
| Employees | 258 | LT Debt/Eq | 0.3 | EPS/Sales Surpr. | -44.23% - | SMA200 | -12.29% ($19.31) | Avg Volume(3M) | 2.78M | Price | $16.94 |
| IPO | 2020/9/17 | Option/Short | Yes/Yes | Trades | 17471 | Volume | 3,000,045 | Change | 7.76% |
A clinical-stage biotech company developing therapeutics for muscle diseases. It leverages targeted delivery technology to develop treatments for rare muscle disorders, including muscular dystrophy, and is attracting attention for its clinical progress. The company is a biotech firm specializing in muscle disease therapeutics.
Over the past 1 year, on the lower side
38% below its 1-year high.
Traded about as much as usual. That is 108% of its average volume.
DYN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -4.5% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +18.6%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 85.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #71 of 594 in the industry
Based on market cap of $3B.
FAQ
What kind of company is DYN?
DYN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DYN?
The market cap of DYN is approximately $3.2B, ranking 1,716 within its sector.
What is the 52-week high and low for DYN?
DYN has recorded a 52-week high of $27.31 and a low of $14.00.
